文献速递淋巴瘤造血干细胞移植与细胞治疗

苯达莫司汀替代BEAM方案中BCNU用于侵袭性淋巴瘤自体干细胞移植预处理:GELTAMO协作组2期研究

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
PubMed 文献 · Br J Haematol · 2018-12-12

该2期试验评估以苯达莫司汀替代BCNU的BendaEAM方案作为侵袭性淋巴瘤自体干细胞移植预处理的安全性和疗效,主要终点为3年无进展生存(PFS)。共纳入60例患者(中位年龄55岁),中位随访67个月,估计3年PFS为58%、总生存(OS)为75%;研究开始时处于部分缓解的患者PFS和OS显著较差,且为多因素分析中唯一与PFS和OS相关的预后因素。

要点

  • BendaEAM预处理后中性粒细胞和血小板植入中位时间分别为11天和14天。
  • 100天和1年非复发死亡率分别为3.3%和6.7%。
  • 研究开始时部分缓解者PFS和OS显著劣于完全代谢缓解者。

核心结论

  • BendaEAM预处理在侵袭性淋巴瘤患者中是可行且有效的方案。
  • 移植时未达完全代谢缓解的患者生存较差,应考虑替代治疗策略。

研究设计与样本

  • GELTAMO协作组开展的2期试验,评估苯达莫司汀替代BCNU的BendaEAM方案作为侵袭性淋巴瘤自体干细胞移植预处理。
  • 共纳入60例患者,中位年龄55(28-71)岁,主要终点为3年无进展生存(PFS)。

主要发现

  • 除1例早期死亡外,所有患者均植入,中性粒细胞>0.5×10^9/L和血小板>20×10^9/L的中位时间分别为11(9-72)天和14(4-53)天。
  • 100天和1年非复发死亡率分别为3.3%和6.7%。
  • 中位随访67(40-77)个月,估计3年PFS为58%,总生存(OS)为75%。
  • 研究开始时部分缓解患者PFS和OS显著劣于完全代谢缓解患者,多因素分析中为唯一与PFS(相对风险[RR] 0.27,95%CI 0.12-0.56)和OS(RR 0.40,95%CI 0.17-0.97)相关的预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem-cell transplantation (ASCT) in patients with aggressive lymphomas. The primary endpoint was 3-year progression-free survival (PFS). Sixty patients (median age 55 [28-71] years) were included. All patients (except one who died early) engrafted after a median of 11 (9-72) and 14 (4-53) days to achieve neutrophil and platelet counts of >0.5 × 109 /l and >20 × 109 /l, respectively. Non-relapse mortality at 100 days and 1 year were 3.3% and 6.7%, respectively. With a median follow-up of 67 (40-77) months, the estimated 3-year PFS and overall survival (OS) were 58% and 75%, respectively. Patients in partial response at study entry had significantly worse PFS and OS than patients who underwent ASCT in complete metabolic remission, and this was the only prognostic factor associated with both PFS (Relative risk [RR], 0.27 [95% confidence interval {CI} [0.12-0.56]) and OS (RR, 0.40 [95% CI 0.17-0.97]) in the multivariate analysis. BendaEAM conditioning is therefore a feasible and effective regimen in patients with aggressive lymphomas. However, patients not in complete metabolic remission at the time of transplant had poorer survival and so should be considered for alternative treatment strategies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Redondo AM, Valcárcel D, González-Rodríguez AP, et al. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Br J Haematol. 2018. PMID: 30548583. doi:10.1111/bjh.15713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。